154P Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Casdozo is the first in class and only clinical-stage IL-27 targeting antibody, which inhibits IL-27 signaling and T and NK cell immune inhibition leading to increased IFN-γ and NK cell gene activation in patients (pts) with cancer. A phase 1 dose-escalation and dose-expansion study of casdozo in advanced solid tumors demonstrated favorable safety and reversal of IL-27-mediated immune suppression. We present updated antitumor activity, safety, and biomarker data of casdozo monotherapy in pts with NSCLC.
Authors
- Nathan A. Pennell (ORCID: https://orcid.org/0000-0002-1458-0064)
- Aung Naing (ORCID: https://orcid.org/0000-0002-4803-8513)
- L. Gandhi
- Anthony B. El-Khoueiry (ORCID: https://orcid.org/0000-0002-9053-3841)
- Angel Qin
- Shinkyo Yoon (ORCID: https://orcid.org/0000-0001-7544-0404)
- Vaishali Kapoor (ORCID: https://orcid.org/0000-0002-7581-1487)
- Charlene Mantia (ORCID: https://orcid.org/0000-0001-7672-3131)
- Daniel Morgensztern (ORCID: https://orcid.org/0000-0003-4349-2028)
- Mehmet Altan (ORCID: https://orcid.org/0000-0001-9229-156X)
- David E. Gerber (ORCID: https://orcid.org/0000-0002-7812-6741)
- Thomas U. Marron (ORCID: https://orcid.org/0000-0001-5903-8191)
- Tae‐Yop Kim (ORCID: https://orcid.org/0000-0003-0806-8969)
- Haicheng Tang (ORCID: https://orcid.org/0000-0002-5270-9965)
- Daniel J. Chin (ORCID: https://orcid.org/0000-0002-2266-9501)
- H.R. Kim
- Koho Iizuka
- L. Villaruz
Institutions
- University of Southern California (US)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Yonsei University (KR)
- Washington University in St. Louis (US)
- Asan Medical Center (KR)
- Seoul National University Hospital (KR)
- University of Ulsan (KR)
- Southwestern Medical Center (US)
- Coherus BioSciences (United States) (US)
- Michigan Medicine (US)
- Dana-Farber Cancer Institute (US)
- Michigan Cancer Research Consortium (US)
- UPMC Hillman Cancer Center (US)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100783
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00